| Victoza (liraglutide) / Novo Nordisk |
| Ongoing | 4 | 24 | Europe | Suspension for injection, Victoza | Allan Vaag, Steno Diabetes Center | Impacted Wisdom teeth, Inferior Alveolar Nerve injury after third molar removal | | | | |
ACTRN12617001613392: Effect of liraglutide on weight loss in patients with inadequate weight loss following bariatric surgery
|
|
|
| Recruiting | 4 | 48 | | | Monash University, Novo Nordisk | Obesity, Failure of adequate weight loss following Laparoscopic Adjustable Gastric Band | | | | |
2010-023226-20: Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion. |
|
|
| Ongoing | 4 | 20 | Europe | Solution for injection, Victoza | KULeuven | healthy volunteersno medical condition; drugs will be studied because they are known to influence gastric motility. | | | | |
ChiCTR-IPR-16008578: Analysis of curative effect of Liraglutide monotherapy, Metformin monotherapy and Liraglutide plus Metformin dual therapy in patients with type 2 diabetes mellitus complicated with coronary artery disease |
|
|
| Completed | 4 | 120 | | Liraglutide ;Metformin; high dose Liraglutide; low dose Liraglutide plus Metformin | Tianjin First Center Hospital; Tianjin First Center Hospital, Funding from the department of Endocrinology, Tianjin First Center Hospital | type 2 diabetes mellitus complicated with coronary artery disease | | | | |
ChiCTR-OCS-13003185: Plasma cytokine and its tissue expression in different glucose tolerance persons |
|
|
| Completed | 4 | 150 | | GLP-1 receptor agonist | the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.; Level of the institution：, NSFC and Key project of chongqing science and technology commission | diabetes and insulin resistance | | | | |
2014-000988-41: Continuous positive airway pressure with or without liraglutide in obstructive sleep apnoea and type 2 diabetes (ROMANCE) |
|
|
| Ongoing | 4 | 152 | Europe | Victoza 6mg/ml solution for injection in pre-filled pens, N/A, Solution for injection in pre-filled pen, Victoza 6 mg/ml solution for injection in pre-filled pen | University of Liverpool | Obstructive Sleep Apnoea and Type 2 Diabetes, Obstructive Sleep ApnoeaType 2 Diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
ChiCTR-TRC-14004660: Comparison of efficacy of liraglutide, metformin and gliclazide MR on hepatic lipid content in patients with type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD) |
|
|
| Not yet recruiting | 4 | 63 | | Liraglutide ;Metformin ;Metformin | Drum Tower Hospital Affiliated to Nanjing University Medical School; Drum Tower Hospital Affiliated to Nanjing University Medical School, Drum Tower Hospital Affiliated to Nanjing University Medical School, Novo Nordisk, Merck Serono, Servier, Johnson | Type 2 Diabetes, Non-alcoholic fatty liver | | | | |
2013-005395-18: Assessing the efficacy and safety of the GLP1-agonist liraglutide in patients who developed diabetes as a consequence of the use of anti-psychotic drugs Onderzoek naar de effecten van het medicijn liraglutide bij patiënten met een type suikerziekte (diabetes) die veroorzaakt is door het gebruik van antipsychotische medicijnen. |
|
|
| Ongoing | 4 | 50 | Europe | Liraglutide, Injection, Liraglutide | University Medical Center Utrecht, University Medical Center | antipsychotic-drugs-associated diabetes mellitus diabetes mellitus veroorzaakt door het gebruik van anti-psychotica, diabetes caused by the use of antipsychotic drugs type suikerziekte die veroorzaakt is door het gebruik van antipsychotische medicijnen, Diseases [C] - Hormonal diseases [C19] | | | | |
| Recruiting | 4 | 40 | | Once a day liraglutide hypodermic injection ;Oral metformin for three months | The First affiliated Hospital of Zhengzhou University; None, Novo nordisk pharmaceutical co., LTD., China | obesity | | | | |
| Ongoing | 4 | 80 | Europe | LIRAGLUTIDE, Solution for injection, VICTOZA | Imperial College London, MOULTON CHARITABLE FOUNDATION | TYPE 2 DIABETES MELLITUS, DIABETES, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2009-015927-94: Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide? |
|
|
| Ongoing | 4 | 36 | Europe | Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets, Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets | Hull and East Yorkshire NHS Trust | Polycystic Ovary SyndromeNon-alcoholic Steatohepatitis | | | | |
2010-020193-42: A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA\'s)+ high doses of insulin. |
|
|
| Ongoing | 4 | 66 | Europe | Victoza (Liraglutide), Glucobay, Victoza (Liraglutide), Victoza, Glucobay, Victoza, Glucobay | Hywel DdA Health Borad | Type-2 Diabetes Mellitus | | | | |
2011-003614-17: Treatment of patients with Liraglutide prior to bariatric sugery |
|
|
| Ongoing | 4 | 46 | Europe | Victoza®, Victoza® | University Medical Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf | Pretreatment of patients with Type 2 diabetes mellitus with expected weight loss surgery (Roux-en-Y Gastric Bypass) | | | | |
2012-005197-63: Effect of liraglutide (antidiabetic drug) on physical performance in patiens with type 2 diabetes. Efecto del tratamiento con liraglutida (medicamento antidiabetico) sobre el rendimiento físico en pacientes con diabetes tipo 2. |
|
|
| Ongoing | 4 | 30 | Europe | Victoza, Victoza | Ana M. Wägner, Novo Nordisk A/S | Patients with Diabetes type 2. Pacientes con Diabetes tipo 2. | | | | |
2013-005075-40: Effect of Liraglutide on lipid synthesis and metabolism after mixed meal. A single-center randomized controlled study. Liraglutidin vaikutus aterian jälkeiseen rasvojen uudismuodostukseen ja aineenvaihduntaan. -Yhden keskuksen satunnaistettu ja lumelääkekontrolloitu tutkimus. |
|
|
| Ongoing | 4 | 26 | Europe | Liraglutide, Liraglutide | Research Programs\' Unit, Diabetes & Obesity, University of Helsinki, Novo Nodisk AG | Type 2 diabetes | | | | |
2014-000397-19: Effects of weight reducing surgery and liraglutide on blood glucose in diabetes. Effecten van gewichtsverminderende chirurgie en liraglutide op bloedsuikerwaarden bij diabetes |
|
|
| Ongoing | 4 | 60 | Europe | liraglutide, liraglutide | University Medical Center Groningen, Novo Nordisk | type 2 diabetes with morbid obesity type 2 diabetes met morbide obesitas | | | | |
| Ongoing | 4 | 20 | Europe | Victoza, Byetta, Victoza, Byetta, Victoza, Byetta | CUB - Hôpital Erasme, Friedreich's Ataxia Research Alliance | Friedreich\'s Ataxia | | | | |
| Ongoing | 4 | 14 | Europe | Victoza, Victoza | KULeuven, KULeuven | healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility | | | | |
2011-001408-37: Effect of Liraglutide on metabolism and function of the left ventricle in patients with type 2 diabetes and heart problems: study with RMN investigations Effetto della Liraglutide sul metabolismo e sulla funzionalita\' del ventricolo sinistro nei pazienti con diabete di tipo 2 e problemi cardiaci : studio di risonanza magnetica. |
|
|
| Ongoing | 4 | 30 | Europe | VICTOZA*SC 2PEN 3ML 6MG/ML, VICTOZA*SC 2PEN 3ML 6MG/ML | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, NOVO NORDISK | patients affected by type 2 diabetes and heart failure pazienti maschi affetti da diabete di tipo 2 e scompenso cardiaco | | | | |
2015-005402-11: GLIDE: Gastric band and Liraglutide Intervention in Diabetes Evolution |
|
|
| Ongoing | 4 | 58 | Europe | Solution for injection, Victoza 6 mg/ml solution for injection in pre-filled pen | Guys and St Thomas NHS Foundation Trust, Novo Nordisk Ltd | Type 2 Diabetes, Type 2 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2016-001523-31: Effect of liraglutide on vascular inflammation in type-2 diabetes Effekten af Liraglutid på vaskulær inflammation hos patienter med type 2 diabetes |
|
|
| Ongoing | 4 | 100 | Europe | Liraglutide, SUB25238, Solution for injection in pre-filled pen, Victoza | Steno Diabetes Center, Novo Nordisk | Type 2 diabetes Type 2 diabetes, Diabetes Sukkersyge, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-000043-40: Study of alternative drug to insulin for the treatment of high blood glucose concentration in cardiac surgery patients |
|
|
| Ongoing | 4 | 274 | Europe | Solution for injection, VICTOZA | Academic Medical Center, Novo Nordisk | Hyperglyceamia during Cardiac Surgery, High blood glucose concentration in patients undergoing cardiac surgery, Body processes [G] - Physiological processes [G07] | | | | |
ChiCTR-IPR-16009666: Effects of liraglutide on inducing long-term clinical remission in newly diagnosed type 2 diabetes after intensive treatment |
|
|
| Recruiting | 4 | 100 | | Liraglutide ;Metformin | Liaocheng City People's Hospital; Liaocheng City People's Hospital, Self-raised funds | Type 2 diabetes | | | | |
ChiCTR1800018008: The effects of liraglutide on beta-cell function and its mechanisms in young patients with new-onset type 2 diabetes |
|
|
| Completed | 4 | 60 | | Liraglutide ;Metformin | Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University; Zhongshan Hospital Xiamen University, Science and Technology Benefit Fund of Xiamen Technology Bureau | type 2 diabetes | | | | |
ChiCTR1800018292: Study for the effect of dapagliflozin combined with insulin pump in type 2 diabetes mellitus |
|
|
| Recruiting | 4 | 87 | | dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d ;insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d. | Teda International Cardiovascular Hospital; Teda International Cardiovascular Hospita, Tianjin Binhai New Area Health and Family Planning Commission science and technology project | Diabetes | | | | |
2018-003575-34: Treatment of bile acid malabsorption with liraglutid Behandling af galdesyremalabsorption med liraglutid |
|
|
| Ongoing | 4 | 44 | Europe | Injection, Tablet, Victoza, Cholestagel | Professor, Ph.d. MD. Filip Krag Knop, Novo Nordisk | Bile acid malabsoprtion is a disease in which there is a large spill-over of bileacids to the larger intestines. This causes watery diarrheas and abdominal symptoms. Galdesyremalabsorption er en sygdom, hvos der er mere galdesyre i tarmsystemet end hos raske individer. Dette giver vandige diarrere og abdominale gener, Bile acid malabsoprtion is a disease in which there is a large spill-over of bileacids to the larger intestines. This causes watery diarrheas and abdominal symptoms. Galdesyremalabsorption er en sygdom, hvos der er mere galdesyre i tarmsystemet end hos raske individer. Dette giver vandige diarrere og abdominale gener, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR1800017538: Comparison of weight loss in patients with polycystic ovary syndrome of glucophage and liraglutide monotherapy or combination treatment: a randomized controlled trial |
|
|
| Recruiting | 4 | 60 | | Glucophage (Bristol-Myers Squibb) 0.85g Po, bid for 12 weeks ;Liraglutide(Novo Nordisk) 0.6 mg injected s.c. qm for 1 week, and increased to 1.2 mg qd for 11 weeks ;Glucophage (Bristol-Myers Squibb) 0.85g Po, bid for 12 weeks and Liraglutide(Novo Nordisk) 0.6 mg injected s.c. qm for 1 week, and increased to 1.2 mg qd for 11 weeks | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-supporting | Polycystic ovarian syndrome | | | | |
2018-001949-13: The effect of a gastrointestinal hormone (GLP-1)agonist on gastrointestinal contractility during the fasted state, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers |
|
|
| Not yet recruiting | 4 | 15 | Europe | Liraglutide, Solution for injection in pre-filled pen, Victoza | KU Leuven, KU Leuven | The study will focus on the underlying mechanisms of obesity. The effects will first be investigated in healthy, lean volunteers., The study will focus on the underlying mechanisms of obesity. The effects will first be investigated in healthy, lean volunteers., Body processes [G] - Metabolic Phenomena [G03] | | | | |
ChiCTR-OPN-17011066: SNPs Study of DPP4 and GLP1R in Chinese and it's Apply in Blood Glucose Regulation With Incretin. |
|
|
| Recruiting | 4 | 150 | | sitagliptin po 100mg qd ;Liraglutide ih, 0.6mg qd for first week and 1.2mg qd for the last 3 weeks | Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, Science & Technology Department of Sichuan Province | Type 2 diabetes mellitus | | | | |
2012-000375-16: Effect of Liraglutide on fatty liver content evaluated by 1H-spectroscopy and lipoprotein kinetic, in patients with type 2 diabetes Effet du Liraglutide sur le contenu en graisse hépatique (évalué par spectroscopie protonique) et sur la cinétique des lipoprotéines chez des patients diabétiques de type 2 |
|
|
| Not yet recruiting | 4 | 120 | Europe | Solution for injection, VICTOZA | CHU Dijon, NovoNordisk | Diabete type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR1900023036: Glucagon-like Peptide-1 Receptor Agonists Regulating Glucose Metabolism by Regulating Intestinal Flora and its Metabolites: A Prospective, Multi-center Clinical Study. |
|
|
| Not yet recruiting | 4 | 30 | | Liraglutide | Department of Endocrinology and Metabolism, Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing | Diabetes | | | | |
ChiCTR1900023465: Using high-resolution nuclear magnetic technique to observe the effects of liraglutide on visceral function and lipid distribution in type 2 diabetes |
|
|
| Recruiting | 4 | 30 | | Liraglutide ;conventional therapy | Tianjin Metabolic Diseases Hospital; Tianjin Metabolic Diseases Hospital, Tianjin Metabolic Diseases Hospital | Type 2 Diabetes | | | | |
ChiCTR1900021593: Comparison of the efficacy and safety of Diane-35 and Drospirenone and Ethinylestradiol Tablets (II) in the treatment of polycystic ovary syndrome: a randomized controlled trial |
|
|
| Not yet recruiting | 4 | 124 | | Diane-35 (2mg ciproterone acetate + 0.035mg ethinylestradiol) for 6 months ;Drospirenone and Ethinylestradiol Tablets (II)(3mg spironetone + 0.002mg ethinylestradiol) for 6 months | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-supporting | Polycystic ovarian syndrome | | | | |
ChiCTR2000030904: Effect of liraglutide combined with empagliflozin on β cell function and blood glucose control in newly diagnosed type 2 diabetic patients with overweight or obesity: a randomized parallel controlled trial |
|
|
| Recruiting | 4 | 312 | | Metformin+Empagliflozin ;Metformin+Liraglutide ;Metformin+traditional oral hypoglycemic agents | Sichuan Academy of Medical Sciences•Sichuan Provincial People's Hospital; Sichuan Academy of Medical Sciences?Sichuan Provincial People's Hospital, self-raised funds | Diabetes | | | | |
ChiCTR1900020647: Study for GLP-1-based drugs on improving insulin sensitivity in newly diagnosis obese type 2 diabetic patients |
|
|
| Recruiting | 4 | 40 | | Liraglutide+Metformin ;glimepiride+Metformin | The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University | diabetes | | | | |
2020-002940-22: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL Effetti dell’agonista recettoriale del GLP-1 liraglutide sulla perfusione degli arti inferiori in individui con diabete tipo 2 e arteriopatia periferica: un trial randomizzato controllato |
|
|
| Not yet recruiting | 4 | 50 | Europe | Liraglutide, [NA], Solution for injection, VICTOZA - 6 MG/ML-SOLUZIONE INIETTABILE IN PENNA PRERIEMPITA - USO SOTTOCUTANEO - CARTUCCIA(VETRO) IN PENNA PRERIEMPITA - 3ML 2 PENNE PRERIEMPITE | A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | Peripheral Artery Disease and type 2 diabetes mellitus Arteriopatia ostruttiva cronica periferica e diabete mellito tipo 2, Peripheral Artery Disease and type 2 diabetes mellitus Arteriopatia ostruttiva cronica periferica e diabete mellito tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR1900024828: Efficacy of liraglutide combined with insulin pump in type 2 diabetes |
|
|
| Recruiting | 4 | 200 | | Insulin pump combined with liraglutide ;Insulin pump | XuZhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine; XuZhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Self-raised funds | diabetes | | | | |
ChiCTR2000034159: The efficacy of Liraglutide in patients with intestinal failure: a prospective, single-center, randomized controlled study |
|
|
| Recruiting | 4 | 60 | | conventional therapy ;Subcutaneous injection of Liraglutide and conventional therapy | Jinling Hospital; Research Institute of General Surgery, Jinling Hospital, the National Natural Science Foundation of China (81470797, 81770531) | Patients with intestinal failure | | | | |
| Not yet recruiting | 4 | 426 | | Integrated therapy ;Integrated therapy combined with Metformin hydrochloride ;Integrated therapy combined with Liraglutide | Department of Dermatology, Chinese PLA General Hospital; Chinese PLA General Hospital, Fundation on Capital Advantagement of Clinical Application | Psoriasis with metabolic syndrom | | | | |
ChiCTR2000031943: Effect of GLP-1 receptor agonist on intramuscular fat content in obese type 2 diabetic patients |
|
|
| Recruiting | 4 | 94 | | Liraglutide combined with dietary intervention ;Dietary intervention | Beijing Hospital, National Center of Gerontology; Beijing Hospital, National Center of Gerontology, Hospital level topics | diabetes | | | | |
NCT04146155: Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease |
|
|
| Recruiting | 4 | 200 | RoW | Liraglutide+standard-of-care treatment, Victoza, standard-of-care treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University | Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus | 12/21 | 12/21 | | |
| Recruiting | 4 | 50 | Europe | Liraglutide, Intervention group, Control, Control group | University of Campania "Luigi Vanvitelli" | Type 2 Diabetes, Peripheral Arterial Disease | 12/21 | 06/22 | | |
| Active, not recruiting | 4 | 69 | US | Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat | The Cleveland Clinic | Type 2 Diabetes, Obesity | 08/22 | 06/23 | | |
ChiCTR2000035887: A Randomized controlled trial for liraglutide plus linagliptin in improving neurological function of patients with acute ischemic stroke and hyperglycemia |
|
|
| Not yet recruiting | 4 | 680 | | Liraglutide plus Liraglutide ;Standard hypoglycemic therapy | Shanghai 6th People's Hospital; Shanghai 6th People's Hospital, Shanghai Shenkang Hospital Development Center | acute ischemic stroke | | | | |
ChiCTR2000037115: Renal efficacy of liraglutide as add-on to glucose-lowering therapy in patients with biopsy proven type 2 diabetic nephropathy: a multi-center, randomised, open-label trial |
|
|
| Not yet recruiting | 4 | 80 | | liraglutide ;standard treatment | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund | Diabetic Nephropathy | | | | |
ChiCTR2000036503: Efficacy of Liraglutide as add-on to glucose-lowering therapy in Patients with biopsy proven Type 2 diabetic nephropathy: a multi-center, randomised, open-label trial |
|
|
| Not yet recruiting | 4 | 156 | | Liraglutide+Standard treatment ;Standard treatment | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund | Diabetic Nephropathy | | | | |
ChiCTR2000035772: Efficacy of Liraglutide as add-on to glucose-lowering therapy in Patients with biopsy proven Type 2 diabetic nephropathy: a single-center, randomised, open-label, controlled, trial |
|
|
| Not yet recruiting | 4 | 160 | | subcutaneous injection of liraglutide ;standard therapy | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund | Diabetic Nephropathy | | | | |
| Completed | 4 | 57 | Europe | Liraglutide, Pioglitazone | University of Leeds | Diabetes Mellitus, Type 2 | 10/22 | 10/22 | | |
NCT06201819: Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery |
|
|
| Completed | 4 | 37 | RoW | Liraglutide injection | Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca | Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid | 03/23 | 05/23 | | |
NCT02344186: Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 12 | US | Liraglutide, Victoza | Temple University | Type 2 Diabetes | 12/22 | 12/23 | | |
ChiCTR2000031879: A prospective randomized controlled clinical study of liraglutide in preventing fractures in postmenopausal women with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 400 | | Application of liraglutide 1.2-1.8mg once a day, subcutaneous injection ;Do not use liraglutide, use biguanides, insulin secretagogues, αglycosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, SGLT-2 inhibitors, basal insulin | Tongji Hospital, Tongji University School of Medicine; Tongji Hospital, Tongji University School of Medicine, Shanghai Shenkang Hospital Development Center | type 2 diabetes mellitus | | | | |
ChiCTR2000036769: A multicenter, randomized, parallel controlled, open-label study on the effects of SGLT2 inhibitor on the renal prognosis of patients with chronic kidney disease with type 2 diabetes |
|
|
| Recruiting | 4 | 300 | | SGLT2i (Dapagliflozin), 5mg qd p.o. ;GLP-1RA (liraglutide), 18 mg/bottle, dosage: once a day, 0.6 mg each time, subcutaneous injection; if there are no obvious adverse reactions, increase to once a day, 1.2 mg each time, before breakfast in the second week Subcutaneous injection; plus dapagliflozin 5mg qd po ;Only use ACEI/ARB, CCB and other antihypertensive drugs, and other antihypertensive drugs | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 2020 Shenkang Precision Diagnosis and Treatment Project for Intractable Diseases | Diabetic Nephropathy | | | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
| Not yet recruiting | 4 | 80 | | Use liraglutide to control glucose | Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, 无 | sepsis with hyperglycemia | | | | |
ChiCTR2200063693: Effect of the glucagon-like peptide-1 receptor agonist on atherosclerosis in patient with impaired glucose tolerance |
|
|
| Not yet recruiting | 4 | 40 | | Intervention to improve life style, including balanced diet (i.e. each person should eat 200g-300g protein, 500g fresh vegetables, 250g Cereals, < 20g vegetable oil, < 6G salt and try to eat less sugar); Regular exercise (i.e. walking for 3 km every day for more than 30 min, at least 5 times a&# ;On the basis of lifestyle improvement intervention, subcutaneous injection of liraglutide / Novolin was given | Qingdao Chengyang District People's Hospital; Chengyang People's Hospital in Qingdao, The Qingdao Medical and health guidance program | impaired glucose tolerance | | | | |
ChiCTR2200057797: An observational study of metformin combined with liraglutide in the treatment of polycystic ovary syndrome with insulin resistance |
|
|
| Recruiting | 4 | 30 | | Metformin and liraglutide | Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University, National Natural Science Foundation of China | polycystic ovary syndrome (PCOS) | | | | |
ZQL007, NCT03883412: Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ) |
|
|
| Recruiting | 4 | 60 | US | Exercise, Liraglutide | University of Virginia, American Diabetes Association, National Institutes of Health (NIH) | Type2 Diabetes | 06/25 | 12/25 | | |
ChiCTR2100049169: Evaluation of the efficacy of liraglutide or glargine in type 2 diabetes patients combined with malignant tumor which treated with glucocorticoid |
|
|
| Not yet recruiting | 4 | 120 | | glargine ;Liraglutide | Affiliated Cancer Hospital of Chongqing University; Affiliated Cancer Hospital of Chongqing University, Application of blood glucose management system in cancer patients with diabetes mellitus (No.: Jcd201965) | diabetes | | | | |
NCT03260881: Liraglutide Effects on Epicardial Fat Inflammatory Genes |
|
|
| Recruiting | 4 | 40 | US | Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens | University of Miami, Novo Nordisk A/S | Type2 Diabetes, Coronary Artery Disease | 10/24 | 10/24 | | |
ChiCTR2000041308: Research on the clinical efficacy and mechanism of Liraglutide in glucocorticoid-induced hyperglycemia |
|
|
| Recruiting | 4 | 16 | | Liraglutide | Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University, Joint Fund of The Affiliated Hospital of Guizhou Medical University, Guizhou Department of Science and Technology | Hyperglycemia | | | | |
ChiCTR2200060695: Effect of pioglitazone metformin combination with liraglutide in patients with type 2 diabetes complicated with metabolometabolic fatty liver disease |
|
|
| Recruiting | 4 | 147 | | Pioglitazone metformin tablets ;Liraglutide injection ;Pioglitazone metformin tablets + Liraglutide injection | Shandong Provincial Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd., Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd. | Type 2 diabetes mellitus with metabolism-related fatty liver disease | | | | |
| Active, not recruiting | 4 | 60 | US | Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation | University of Miami | Atrial Fibrillation | 12/24 | 12/24 | | |
ChiCTR1900026485: Efficacy and safety of liraglutide in the treatment of newly-diagnosed overweight / obesity type 2 diabetes mellitus: a single-center, randomized, parallel controlled trial |
|
|
| Not yet recruiting | 4 | 192 | | liraglutide; metformin | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Affiliated Hospital of Guangdong Medical University | newly-diagnosed overweight / obesity type 2 diabetes mellitus | | | | |
ChiCTR2300074947: Effect of liraglutide on depressive status in patients with type 2 diabetes mellitus and major depressive disorder: a single-center, observational cohort study |
|
|
| Not yet recruiting | 4 | 100 | | NA ;NA | Peking University Third Hospital; Peking University Third Hospital, N/A | type 2 diabetes mellitus and major depressive disorder | | | | |
ZQL008, NCT04575844: Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome |
|
|
| Recruiting | 4 | 80 | US | Liraglutide, Exercise training, Liraglutide + Exercise training | University of Virginia, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Metabolic Syndrome | 04/25 | 04/25 | | |
| Recruiting | 4 | 40 | US | growth hormone and lirglutide, growth hormone, liraglutide, Placebo | Columbia University | Healthy, Growth Hormone Deficiency | 04/28 | 04/28 | | |
2017-000349-30: Effect of INtervention with DMR, GLP-1 and lifestyle intensification -in Subjects with insulin dePendent type 2 diabetes- on Insulin Requirement and mEtabolic parameters Effect van interventie met DMR, GLP-1 en lifestyle intensivering -bij patiënten met insulineafhankelijke type 2 diabetes- op insulinebehoefte en metabole parameters |
|
|
| Ongoing | 3/4 | 16 | Europe | Victoza, EMA/354054/2016, Solution for injection in pre-filled pen, Victoza (Liraglutide) | Academic Medical Center, Fractyl Laboraties Inc. | Type 2 diabetes mellitus Diabetes mellitus type 2, Type 2 diabetes Suikerziekte type 2, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2013-002348-99: The effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus Mελέτη της επίδρασης της λιραγλουτίδης στην αρτηριακή πίεση υπερτασικών ασθενών με σακχαρώδη διαβήτη τύπου 2 |
|
|
| Ongoing | 3 | 112 | Europe | VIctoza, Solution for injection in pre-filled pen, Victoza | Aristotle University Thessaloniki, NOVO NORDISK HELLAS | Hypertention, Type 2 Diabetes Υπέρταση, Διαβήτης τύπου 2, Hypertention, Diabetes Υπέρταση, Διαβήτης, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2011-001538-41: GLIDE: Gastric band and Liraglutide Intervention in Diabetes Evolution |
|
|
| Ongoing | 3 | 200 | Europe | Liraglutide, Victoza 6 mg/ml solution for injection in pre-filled pen, Victoza 6 mg/ml solution for injection in pre-filled pen | University of Birmingham | This trial will investigate the effects of the study treatment arms (gastric band + placebo; gastric band + liraglutide) on diabetes resolution in obese patients. | | | | |
2011-004955-38: Controlling Glucose during Elective hip Surgery to study the influence on Coagulation |
|
|
| Ongoing | 3 | 36 | Europe | Victoza, EMEA/H/C/001026, Victoza, Victoza | AMC, Amsterdam, AMC, Amsterdam, Novo Nordisk | patients who will undergo elective hip surgery with a hyperglycemic period perioperatively due to surgery. | | | | |
2010-024024-14: INVESTIGACION DE LA OBESIDAD EN LAS INCRETINAS:EVALUACIÓN DE NUEVOS TRATAMIENTOS DE DIABETES.EFECTO DE LOS TRATAMIENTOS CON INSULINA, LIRAGLUTIDE Y CIRUGÍA BARIÁTRICA EN LA MEJORIA DE LA DIABETES TIPO II EN PACIENTES CON OBESIDAD GRADO I |
|
|
| Ongoing | 3 | 150 | Europe | VICTOZA 6 mg/ml solución inyectable en pluma precargada, DIANBEN 850 mg comprimidos recubiertos con película, LEVEMIR 100 U/ml, solución inyectable en una pluma precargada, VICTOZA 6 mg/ml solución inyectable en pluma precargada, DIANBEN 850 mg comprimidos recubiertos con película, LEVEMIR 100 U/ml, solución inyectable en una pluma precargada | CAIBER | DIABETES MELLITUS TIPO II (DMTII) | | | | |
2014-003298-40: STUDY OF THE EFFICACY AND SAFETY OF LIRAGLUTIDE IN TYPE 2 DIABETIC PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROME. IMPACT ON CARDIOVASCULAR RISK FACTOR. ESTUDIO DE LA EFICACIA Y SEGURIDAD DE LIRAGLUTIDA EN EL PACIENTE DIABÉTICO TIPO 2 HOSPITALIZADO CON SÍNDROME CORONARIO AGUDO. IMPACTO SOBRE FACTOR DE RIESGO CARDIOVASCULAR. |
|
|
| Ongoing | 3 | 80 | Europe | liraglutide, glargine insulin, VICTOZA, LANTUS, VICTOZA, LANTUS | Instituto de Investigación La Fe, Instituto de Investigación Sanitaria La Fe | TYPE 2 DIABETIC HOSPITALIZED PATIENTS WITH ACUTE CORONARY SYNDROME. PACIENTE DIABÉTICO TIPO 2 HOSPITALIZADO CON SÍNDROME CORONARIO AGUDO. | | | | |
ACTRN12613001069741: The combined effect of Liraglutide and Sleeve Gastrectomy on Metabolic, Cardiac, Neurological and Sleep Function in Obese Diabetes: A Twelve-Month Randomised Study. |
|
|
| Active, not recruiting | 3 | 120 | | | Northern Sydney Local Health District, Novo Nordisk | Type 2 Diabetes Mellitus, Obesity | | | | |
2017-005032-42: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease Effekt von Liraglutid auf das Stoffwechselprofil in Patienten mit Typ 2 Diabetes und Herz-Kreislauf-Erkrankung |
|
|
| Not yet recruiting | 3 | 50 | Europe | Liraglutid, Injection, Victoza | RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty, Novo Nordisk | Diabetes Type 2 with existing cardiovascular disease Diabetes Typ 2 mit bestehender kardiovaskulärer Erkrankung, Diabetes Type 2 with existing cardiovascular disease Diabetes Typ 2 mit bestehender Herz-Kreislauf-Erkrankung, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT03986008: Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients |
|
|
| Recruiting | 3 | 60 | RoW | Benaglutide, rhGLP-1(7-36), Liraglutide, Victoza | Xiangya Hospital of Central South University | Obesity | 12/21 | 12/21 | | |
NCT04487743: Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities |
|
|
| Recruiting | 3 | 300 | RoW | Liraglutide, S20200402, placebo, S20200301 | Xiangya Hospital of Central South University | Obesity | 06/22 | 06/22 | | |
NCT04525300: Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities |
|
|
| Recruiting | 3 | 300 | RoW | Liraglutide, S20200402, placebo, S20200301 | Xiangya Hospital of Central South University | Obesity | 06/22 | 06/22 | | |
NCT03671733: Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients |
|
|
| Recruiting | 3 | 150 | RoW | Liraglutide, Victoza, Exenatide, Byetta, Exenatide Microspheres for Injection, Bydureon | Xiangya Hospital of Central South University | Obesity | 09/22 | 09/22 | | |
NCT04605861: The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients |
|
|
| Completed | 3 | 414 | RoW | Liraglutide, Placebo | Shanghai Zhongshan Hospital | Obese, Overweight | 12/22 | 04/23 | | |
| Recruiting | 3 | 478 | | Liraglutide injection ;Novol injection | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Chongqing Chen 'an Bio-Pharmaceutical Co. Ltd | Type 2 diabetes | | | | |
NCT05467514: Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 3 | 35 | RoW | Liraglutide | David Sanchez Garcia, Instituto Mexicano del Seguro Social | Diabetes Mellitus, Type 1 | 02/23 | 02/23 | | |
| Active, not recruiting | 3 | 78 | Europe, US, RoW | Liraglutide, Placebo | Novo Nordisk A/S | Obesity | 08/23 | 01/27 | | |
NCT02516657: Liraglutide in Adolescents With Type 1 Diabetes |
|
|
| Active, not recruiting | 3 | 5 | US | Liraglutide, Victoza | University at Buffalo | Type 1 Diabetes | 12/23 | 12/24 | | |
NCT06361238: Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery |
|
|
| Not yet recruiting | 3 | 260 | NA | Liraglutide injection, Victoza, Placebo injection, Normal saline | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Delirium, Postoperative | 03/26 | 03/27 | | |
NCT05952882: Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility |
|
|
| Not yet recruiting | 3 | 188 | NA | Liraglutide + Metformin, LIME, Metformin, MET | Mỹ Đức Hospital | Polycystic Ovary Syndrome, Obesity, Infertility, Female | 12/25 | 12/25 | | |
2012-001208-39: A new therapeutic approach to prevent acute complications in type 2 diabetes: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® against the cOnventional insulin therapy: GALILEO Neuer Therapieansatz zur Verhinderung akuter Komplikationen bei Typ 2 Diabetes: Der Effekt einer Kombination des GLP-1 Analogons Liraglutide mit Insulin LEvemir im Vergleich zur kOnventionellen Insulintherapie: GALILEO |
|
|
| Ongoing | 2 | 32 | Europe | Insulin Levemir, Victoza, insulin aspart, EMEA/H/C/000528, EMEA/H/C/001026, EMEA/H/C/000308, Injection | Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel, Medizinische Universität Wien | diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapymyocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunction Diabetes mellitus Typ 2,unzureichende Stoffwechselkontrolle, Indikation für InsulintherapieMyokardiale Lipidakkumualtion und Herzfunktion, retinale Veränderungen, Mikroalbuminurie, Beta-Zell-Funktion, Ednotheliale Dysfunktion, Typ 2 Diabetes, bad metabolic control, need for insulin therapyacute secondary diabetes-related complications Typ 2 Diabetes, schlechte Stoffwechseleinstellung, insulinpflichtigakute Folgeerkrankungen, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2011-003335-63: Effects of liraglutide on pancreatic function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. Effetti di liraglutide sulla funzione pancreatica nei pazienti con diabete tipo 2 in fallimento secondario agli ipoglicemizzanti orali. |
|
|
| Ongoing | 2 | 80 | Europe | Solution for injection, Tablet, Coated tablet, VICTOZA*SC 2PEN 3ML 6MG/ML, GLIMEPIRIDE TEVA*20CPR 4MG, LEVEMIR*FLEX 5PEN 3ML 100UI/ML, METFORMINA TEVA IT*60CPR RIV1G | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, UNIVERSITA' DI PISA, NOVO NORDISK | Type 2 Diabetes mellitus Diabete mellito tipo 2, Type 2 Diabetes Diabete tipo 2, Diseases [C] - Hormonal diseases [C19] | | | | |
2015-000825-35: Liraglutide to Short Bowel Syndrome, a cross-over study Liraglutide til jejunostomipatienter, et overkrydsningsstudie |
|
|
| Ongoing | 2 | 16 | Europe | Solution for injection in pre-filled pen, Victoza | Rigshospitalet Blegdamsvej, Rigshospitalet Blegdamsvej | Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; restricted oral/enteral nutrition to reduce intestinal losses; disease-related hypophagia; lack of adaptive hyperphagia; accelerated gastrointestinal transit time, Patients with a jejunostomy and a short bowel syndrome, Diseases [C] - Digestive System Diseases [C06] | | | | |
2011-003572-36: The role of gut hormones replacement in improving blood flow to the brain after stroke that affects swallowing. |
|
|
| Ongoing | 2 | 40 | Europe | Liraglutide, Liraglutide, Liraglutide | Royal Devon & Exeter NHS Foundation Trust, University of Exeter, , University of Exeter | We plan to give a synthetic form of GLP-1 (Liraglutide) that is already available and licensed for use in patients with diabetes in the UK, to patients who have had an acute stroke, in order to determine whether increased levels protect the brain during its recovery, resulting in better recovery. | | | | |
2012-002073-60: Liraglutide in the treatment of polycystic ovary syndrome (LIPOS study) |
|
|
| Ongoing | 2 | 106 | Europe | Liraglutide (Victoza), Victoza, Victoza | University of Warwick, Novo Nordisk Ltd | Polycystic ovary syndrome (PCOS). | | | | |
2014-001381-96: A trial investigating liraglutide on the liver glucose production during induced hypoglycaemic in type 1 diabetes mellitussubjects |
|
|
| Ongoing | 2 | 15 | Europe | Victoza, Victoza | Medizinische Universität Graz / Endokrinologie und Stoffwechsel, Medizinische Universität Graz / Endokrinologie und Stoffwechsel | Diabetes Mellitus Type 1 | | | | |
2016-002045-36: Lifestyle induced weight loss and Liraglutide in the treatment of NASH |
|
|
| Ongoing | 2 | 50 | Europe | Victoza, Suspension for injection, Victoza | University of Oxford, Clinical Trials and Research Governance, University of Oxford | Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease - fat and inflammation in the liver, Diseases [C] - Digestive System Diseases [C06] | | | | |
2016-004797-18: A pilot study in the use of the GLP-1 agonist liraglutide in the treatment of short bowel |
|
|
| Ongoing | 2 | 5 | Europe | Victoza, EU/1/09/529/001-005, Solution for injection in pre-filled pen, Victoza | Imperial College London, St Mark's Foundation | Intestinal failure with an underlying aetiology of short bowel, Intestinal failure due to short bowel is defined as a condition whereby a patient has insufficient intestinal length to absorb enough fuilds and/or nutrients to sustain life without IV supplementation, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-000043-31: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients Efficacité et tolérance du Liraglutide sur la perte de poids chez les patients hémodialysés diabétiques de type 2 obèses |
|
|
| Not yet recruiting | 2 | 30 | Europe | Liraglutide, Injection, Liraglutide | Groupe Hospitalier Paris Saint-Joseph, Groupe Hospitalier Paris Saint-Joseph | obese type 2 diabetic hemodialysis patients, obese type 2 diabetic hemodialysis patients, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2020-005098-29: OPTI-STEMI is a randomized, non-profit, open label, multicentre phase II trial for the evaluation of new therapeutic strategies to reduce microvascular obstruction and to optimize revascularization in non-culprit stenosis in STEMI myocardial infarction. OPTI-STEMI è uno studio randomizzato, no-profit, open label, multicentrico di fase II per la valutazione di nuove strategie terapeutiche per ridurre l’ostruzione microvascolare e per ottimizzare la rivascolarizzazione in stenosi non-culprit nell’infarto miocardico STEMI. |
|
|
| Ongoing | 2 | 520 | Europe | Metoprololo, Atorvastatina, Eparina sodica, Adenosina, Colchicina, Clopidogrel, Ticagrelor, Liraglutide, Prasugrel, Ramipril, Acido acetilsalicilico, Abciximab, [NA], Infusion, Tablet, Solution for injection | DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Ministero dell’Istruzione, dell’Università e della Ricerca Progetto MIUR codice 2017PZY5K7 | Patients with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) defined by at least one non-culprit stenosis (NCS) with angiographic severity between 30 and 90% Pazienti infarto miocardico acuto con sopraslivellamento del tratto ST (STEMI) e con malattia coronarica multivasale (MVD) definita da almeno una stenosi non culprit (NCS) con severità angiografica tra il 30 ed il 90%, Patients with microvascular obstruction with non-culprit stenosis, i.e. with partial stenosis, between 30% and 90%, of coronary vessels. Pazienti con ostruzione microvascolare con stenosi non-culprit, ossia con stenosi parziale, tra il 30% e il 90%, dei vasi coronarici., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
LIRADIAL, NCT04529278: Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients |
|
|
| Active, not recruiting | 2 | 18 | Europe | Liraglutide | Groupe Hospitalier Paris Saint Joseph | Diabetes Mellitus, Type 2, Hemodialysis, Obese | 01/23 | 12/23 | | |
NATRIURETIC, NCT04535960: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "" Trial |
|
|
| Recruiting | 2 | 36 | Canada | Empagliflozin 25 MG + Liraglutide 1.8 MG, Generic names are above, listed, Liraglutide 1.8 MG + Empagliflozin 25 MG | University Health Network, Toronto | Type 2 Diabetes Mellitus | 10/23 | 10/23 | | |
NCT04763564: Efficacy of Liraglutide Therapy in Patients With IPAA |
|
|
| Completed | 2 | 8 | US | Liraglutide Pen Injector, Victoza, Placebo Pen Injector, Saline | University of North Carolina, Chapel Hill, Novo Nordisk A/S | Pouchitis, Irritable Pouch Syndrome | 10/23 | 10/23 | | |
| Enrolling by invitation | 2 | 42 | Europe | Victoza®, Placebo | University of Oulu, Oulu University Hospital, Tampere University Hospital, Turku University Hospital | Health behaviour change, Physical inactivity, Quality of life | 06/24 | 06/24 | | |